Back to Search
Start Over
735MO Updated safety and efficacy from SURPASS, the phase I trial of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in previously treated patients with unresectable or metastatic tumors
- Source :
- Annals of Oncology. 33:S879-S880
- Publication Year :
- 2022
- Publisher :
- Elsevier BV, 2022.
- Subjects :
- Oncology
Hematology
Subjects
Details
- ISSN :
- 09237534
- Volume :
- 33
- Database :
- OpenAIRE
- Journal :
- Annals of Oncology
- Accession number :
- edsair.doi...........7aa3d0c7cafe3366c9abe021e90e28d2
- Full Text :
- https://doi.org/10.1016/j.annonc.2022.07.861